Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT07864064
Starting soon Observational

Comparison of Quadro-Iliac Plane Block and Transversalis Fascia Plane Block for Open Inguinal Hernia Repair

NCT07864064 · tracked via the Priya Life Science Turkey tracker
Sponsor
Vezirköprü State Hospital
Phase
Observational
Started
2026-10-30
Last updated
2026-10-07

Condition(s) studied

Inguinal Hernia Unilateral

Investigational drug(s) / intervention(s)

Quadro iliac Plane BlockTransversalis Fascia Plane Block

Quadro iliac Plane Block: Ultrasound-guided quadro-iliac plane block (QIPB) performed as part of routine clinical practice. In patients receiving QIPB, 40 mL of 0.25% bupivacaine is administered into the quadro-iliac plane.

Transversalis Fascia Plane Block: Ultrasound-guided transversalis fascia plane block (TFPB) performed as part of routine clinical practice. In patients receiving TFPB, 30 mL of 0.25% bupivacaine is administered into the transversalis fascia plane.

Study summary

This prospective observational cohort study aims to compare the postoperative analgesic effectiveness of the quadro-iliac plane block (QIPB) and transversalis fascia plane block (TFPB) in patients undergoing elective unilateral open inguinal hernia repair under spinal anesthesia. The choice of block technique will be determined by the attending anesthesiologist as part of routine clinical practice, independently of study participation, and no randomization or study-directed assignment will be performed. Patients receiving QIPB or TFPB will be prospectively followed as two cohorts. Postoperative pain scores at rest and during coughing will be assessed at 2, 4, 6, 12, and 24 hours. Time to first rescue analgesic requirement, rescue tramadol use, block performance time, and adverse events will also be compared between the two cohorts.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 75 years. * American Society of Anesthesiologists (ASA) physical status I-II. * Scheduled for elective unilateral open inguinal hernia repair. * Eligible to undergo spinal anesthesia. * Provision of written informed consent to participate in the study. Exclusion Criteria: * Refusal to participate in the study. * Contraindication to spinal anesthesia or peripheral nerve/interfascial plane block. * Coagulopathy or clinically significant bleeding disorder. * Infection at the block injection site. * Known allergy to local anesthetics or any medication used in the study. * Chronic opioid use or regular use of analgesic or anticonvulsant medications that may affect pain perception. * Communication or cognitive impairment that prevents reliable NRS assessment. * Inadequate or failed spinal anesthesia or requirement for conversion to general anesthesia.

Primary outcome measure(s)

  • Postoperative Pain Intensity at Rest — At 2, 4, 6, 12, and 24 hours postoperatively
    Postoperative pain intensity at rest will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).
  • Postoperative Pain Intensity During Coughing — At 2, 4, 6, 12, and 24 hours postoperatively
    Postoperative pain intensity during coughing will be assessed using the 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain).

Trial sites (1)

FacilityCityRegionStatus
Vezirköprü state hospital Samsun Samsun

More Vezirköprü State Hospital trials in Turkey

Comparison of TLIP Block and QIP Block for Postoperative Analgesia After Lumbar Spine Surgery Starting soon

Other trials for the same condition

Postoperative Ozonated Oil Dressing After Open Inguinal Hernia Repair: A Randomized Pilot Trial Recruiting
Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia Repair Starting soon
Intrathecal Morphine and Transversalis Fascia Plane Block for Analgesia After Open Inguinal Hernia Repair Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07864064 on ClinicalTrials.gov ↗ ← All trials in Turkey